What is Ibrutinib?

Category: Prescription Drugs

Most popular types: Imbruvica

false

Ibrutinib is an experimental drug being tested for the purposes of treating cancers related to B-cells, which are a part of the immune system. This drug acts by inhibiting Bruton’s tyrosine kinase, a key component of the B-cell signalling pathway.

Reported purpose & perceived effectiveness
Purpose Patients Evaluations Perceived Effectiveness
Chronic lymphocytic leukemia 6 13
B cell prolymphocytic leukemia 2 6
Decreased appetite 1 0
Diffuse large B-cell lymphoma 1 0
Multiple myeloma 1 1
Non-Hodgkin's lymphoma 1 0

Show all 7 reasons taken


  • Major
  • Moderate
  • Slight
  • None
  • Can't tell

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 2
Moderate 4
Mild 13
None 2

Commonly reported side effects and conditions associated with Ibrutinib

Side effect Patients
Diarrhea 3
Dry skin 2
Fatigue 2
Thrombocytopenia (low platelet count) 2
Bruising 1
Bruising of legs 1

Show all 16 reported side effects

Dosages

Based on patients currently taking Ibrutinib

Dosage Patients
280 mg daily 3
420 mg daily 2
560 mg daily 2
70 mg monthly 1
3 capsule(s) daily 1
700 mg daily 1

Why patients stopped taking Ibrutinib

Multiple reasons could be selected

Reason Patients
Did not seem to work 1
Side effects too severe 1
See all 2 patients who've stopped taking Ibrutinib

Duration

Currently taking Ibrutinib

Duration Patients
6 months - 1 year 2
1 - 2 years 2
2 - 5 years 7

Stopped taking Ibrutinib

Duration Patients
1 - 6 months 1
1 - 2 years 1
Adherence
Adherence Evaluations
Always 19
Usually 2
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 0
A little hard to take 0
Not at all hard to take 21
Cost per month
Cost per month Evaluations
$200+ 5
$100-199 0
$50-99 3
$25-49 0
< $25 10
Not specified 3

What people switch to and from

Patients started taking Ibrutinib after stopping:

Treatment Patients
Bendamustine (Bendeka) 2
Rituximab (Rituxan) 2
Bortezomib-dexamethasone (Vd) 1
Dronabinol (Marinol) 1
Methotrexate (Apo-Methotrexate) 1

Patients stopped taking Ibrutinib and switched to:

Treatment Patients
Bendamustine (Bendeka) 1
Rituximab (Rituxan) 1
Last updated:
There are no evaluations for Ibrutinib.